We use cookies for analytics and ads to improve your experience. You can accept or decline. See our Privacy Policy.
Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Valuation
Financials (FY2024)
Investment Thesis
Zak Venture Limited is a Noida-based Ayurvedic and Unani pharmaceutical manufacturer with revenue of ₹24.8 Cr in FY2024, placing it at the upper edge of nano-scale. After strong growth in FY2023, revenue contracted sharply by ~24% in FY2024, raising questions about client concentration or market disruption. As a 100% promoter-held unlisted company in a niche but growing herbal health segment, its outlook hinges on reversing the revenue slide and building a broader product and distribution base.
Pros
Cons
Business Segments
Manufacture of Ayurvedic pharmaceutical preparations
Manufacture of Unani pharmaceutical preparations
Medicinal chemicals and botanical products
Revenue Model
Zak Venture Limited likely generates revenue through manufacturing and/or trading of Ayurvedic and herbal pharmaceutical products, sold through pharmaceutical distribution networks, retail pharmacies, and potentially direct-to-consumer channels.
Detailed Analysis
Growth Plans
Rising consumer demand for natural and Ayurvedic healthcare products in India
Government of India's promotion of AYUSH sector and herbal products
Industry Tailwinds
Rising consumer demand for natural and Ayurvedic healthcare products in India
Government of India's promotion of AYUSH sector and herbal products
Recent Developments
Comparable Companies
DABUR · 80000+ Cr
Frequently Asked Questions
About Zak Venture
Zak Venture Limited is a Noida-based public limited company incorporated on March 14, 2016, specialising in the manufacture of Ayurvedic and Unani pharmaceutical preparations. The company is registered at Office No. 2502, 5th Floor, Tower No. 02, Express Trade Tower 2, Plot No. 36, Block-B, Sector-132, Gautam Buddha Nagar (Noida), Uttar Pradesh — a prestigious commercial address in Noida's business district. The company's industry classification under MCA is "Manufacture of Ayurvedic or Unani Pharmaceutical Preparation," placing it in the rapidly growing traditional medicine and wellness segment of India's healthcare industry. With a CIN of U24233UP2016PLC077163, the company is registered with the Registrar of Companies, ROC Kanpur. Financially, Zak Venture reported revenue of ₹24.8 crore in FY2024, reflecting a 1-year revenue CAGR of -24%, indicating a notable decline in revenues compared to prior years. However, its EBITDA CAGR is 8% over the same period, suggesting that while the top line is under pressure, the company has maintained some profitability resilience. The authorised share capital is ₹20 crore with paid-up capital of approximately ₹4.44 crore. As of February 2024, the company had a team size of 28 employees — a small organisation consistent with a focused SME in the herbal pharmaceutical segment. The last AGM was held on September 30, 2024, indicating active regulatory compliance. India's Ayurvedic and herbal pharmaceutical market has experienced significant growth, particularly following the COVID-19 pandemic which amplified consumer interest in traditional health products, immunity boosters, and herbal remedies. The Ministry of AYUSH's active promotion and the government's target to make India a global hub for AYUSH products provide a supportive policy environment. However, the sector is highly fragmented with intense competition from established players like Dabur, Patanjali, Himalaya, and Emami, as well as hundreds of regional Ayurvedic manufacturers. Zak Venture's competitive strategy likely involves niche product focus within the Ayurvedic formulation space, possibly in specific therapeutic categories or B2B supply to larger herbal brands and distributors. The company's registered office in Noida's commercial district suggests a marketing and distribution-focused business model rather than large-scale manufacturing.
Key Milestones
Common questions about unlisted shares
You buy from and sell to the wisefolio desk — shares route through the desk's demat, money-in before shares-out.
You enquire
· Takes 2 minutesTell us the company and quantity you want. Share your demat details so we can settle directly into your account.
We source & quote
· Typically within 1 business dayOur desk sources the shares and comes back with a firm price and an allocation for the quantity available.
You accept the allocation
· Quote valid for 3 daysReview the price, quantity and total. Accept to lock the allocation. The quote is valid for a short window before it needs re-pricing.
You transfer the funds
· Pay within 2 days of acceptingPay by direct bank transfer to the desk's published account — never to a personal account. We confirm receipt and begin the transfer.
Shares reach your demat
· Usually credited within 2–3 business daysOnce payment is verified, the shares are transferred from the desk's demat into yours, and you receive a transfer confirmation.
A principal desk for unlisted & pre-IPO shares — you transact with us, not a stranger.
You enquire
Takes 2 minutes
We source & quote
Typically within 1 business day
You accept the allocation
Quote valid for 3 days
You transfer the funds
Pay within 2 days of accepting
Shares reach your demat
Usually credited within 2–3 business days
Unlisted shares are illiquid and carry higher risk. Pricing is indicative, not live, and these are private off-market transactions with no exchange settlement guarantee. Read the full risk disclosure.
Industry Headwinds
Intense competition from entrenched Ayurvedic brands with strong distribution networks
Regulatory risks from AYUSH quality and licensing compliance requirements
Revenue declining at -24% 1-year CAGR in FY2024 — market share loss or demand weakening
Source: Company Financial Filings
Very small scale (28 employees, ₹24.8 crore revenue) limits competitive capability
Source: Company Financial Filings
Limited public information on management, products, and business strategy
Source: Media Reports / Public Records
Competes against large established brands like Dabur, Himalaya Drug Company, Patanjali Ayurved, and Zandu in the Ayurvedic products market
Ayurvedic products are regulated by AYUSH Ministry; compliance with quality and labelling standards is critical and can be a barrier for small companies
No publicly available financials or management disclosures make independent assessment of investment risk impossible
PE: 50xx
Unlisted
EMAMILTD · 15000+ Cr
PE: 35xx
Incorporated on 14 March 2016 in Uttar Pradesh under ROC
Registered at Office No. 2502, 5th Floor, Tower No. 2, Express Trade Tower 2, Sector-132, Noida, UP 201301
Authorized capital: ₹2.00 Cr; Paid-up capital: ₹0.44 Cr
Promoter holding: 100% — entirely promoter-owned
FY2023: Revenue grew 51.87% YoY and profitability grew 25.12% — strong prior growth now reversed
Be the first to discuss Zak Venture — share your research, ask questions, or compare notes with other investors.